Rui Medeiros: Calling for Precision Cancer Medicine to Move from Innovation to Implementation
Rui Medeiros / LinkedIn

Rui Medeiros: Calling for Precision Cancer Medicine to Move from Innovation to Implementation

Rui Medeiros, President and Board Of Directors at ECL, Professor/Coordinator Molecular Oncology and Viral Pathology GRP-Research Center at IPO Porto, shared a post on LinkedIn:

“In Science we Trust, In People we Believe.

Working for more than 25 years on the field of Pharmacogenomics and Precision Medicine (research and teaching) glad to be part of this
new ECO report that calls for precision cancer medicine to move from innovation to implementation.

30 June 2026,

Medeiros R, Ryll B (2026). Delivering Precision Cancer Medicine at Scale: An ECO Policy Action Report; European Cancer Organisation; Brussels.

On The Report:

The European Cancer Organisation has published a new policy action report, titled ‘Delivering Precision Cancer Medicine at Scale’, calling for stronger European action to ensure that advances in precision cancer medicine are translated into equitable patient access.

Precision cancer medicine is already changing cancer care. Advances in genomics, molecular diagnostics, biomarker-driven therapies, advanced diagnostics, imaging, image-guided local treatments and data-enabled clinical decision-making are helping to reshape how cancer is diagnosed and treated across Europe. Yet access to these innovations remains uneven. Too often, a patient’s ability to benefit from precision cancer medicine is still shaped by where they live, the capacity of their health system, the availability of molecular testing, reimbursement pathways, workforce expertise and the strength of local data infrastructure.

The report, developed following ECO’s Community 365 Roundtable on equitable access to precision cancer medicine, argues that Europe’s central challenge is no longer only scientific. The question is increasingly one of implementation. Europe already has many of the tools, technologies, clinical advances and policy frameworks needed to support wider access to precision cancer medicine. The priority now is to ensure that these advances can be delivered consistently, sustainably and fairly across European health systems.”

Report available here

Rui Medeiros

Other articles about The European Cancer Organisation on OncoDaily.